|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0012634,
umls-concept:C0015965,
umls-concept:C0020971,
umls-concept:C0021289,
umls-concept:C0035439,
umls-concept:C0086418,
umls-concept:C0140430,
umls-concept:C0312853,
umls-concept:C0439234,
umls-concept:C0596545,
umls-concept:C1708528
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-9-29
|
|
pubmed:abstractText |
For 40 years prophylactic anti-D has been given to D-negative women after parturition to prevent haemolytic disease of the fetus and newborn. Monoclonal or recombinant anti-D may provide alternatives to the current plasma-derived polyclonal IgG anti-D, although none of them have yet proved as effective in phase 1 clinical trials. The variation in efficacy of the antibodies may have been influenced by heterogeneity in glycosylation of anti-D produced from different cell lines. Some aspects of the conduct of the human studies, most notably the use of low doses of anti-D and target D positive red cells in vivo, may aid the design of the clinical development of other immunomodulatory drugs in order to minimize adverse effects.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-10216909,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-10764836,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-11286688,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-11889899,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-11951031,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-13699661,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-14105934,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-14641860,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-14976055,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-14984503,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-15113381,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-15878975,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-16322478,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-16580863,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-16888140,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-16965599,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-17554071,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-17680827,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-17683353,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-18190459,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-1824267,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-18279459,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-1952948,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-1978026,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-3095989,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-4109155,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-7506033,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-7655002,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-7923878,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-814913,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18727626-9126378
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1365-2249
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
154
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1-5
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18727626-Clinical Trials as Topic,
pubmed-meshheading:18727626-Erythroblastosis, Fetal,
pubmed-meshheading:18727626-Female,
pubmed-meshheading:18727626-Fetus,
pubmed-meshheading:18727626-Humans,
pubmed-meshheading:18727626-Infant, Newborn,
pubmed-meshheading:18727626-Isoantibodies,
pubmed-meshheading:18727626-Pregnancy,
pubmed-meshheading:18727626-Rh Isoimmunization,
pubmed-meshheading:18727626-Rh-Hr Blood-Group System
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn.
|
|
pubmed:affiliation |
Bristol Institute for Transfusion Sciences, International Blood Group Reference Laboratory, National Blood Service, NHS Blood and Transplant, Bristol, UK. belinda.kumpel@nbs.nhs.uk
|
|
pubmed:publicationType |
Journal Article,
Review
|
